Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in
combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma previously treated with a BTKi.